Evidence map›Paper›PMID 37788737›Full record

ArticleActa biomaterialia2023

Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.

Duy T Nguyen, Ruixuan Liu, Elizabeth Ogando-Rivas, Alfonso Pepe, Diego Pedro, Sadeem Qdaisat, Nhi Tran Yen Nguyen, Julia M Lavrador, Griffin R Golde, Ryan A Smolchek and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta biomaterialia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Applications of Intravital Imaging in Cancer Immunotherapy.Bioengineering (Basel, Switzerland) · 2024
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Duy T NguyenDepartment of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL 32610, United States.
Ruixuan LiuLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, University of Florida Brain Tumor Immunotherapy Program, Gainesville, FL 32611, United States.
Elizabeth Ogando-RivasLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, University of Florida Brain Tumor Immunotherapy Program, Gainesville, FL 32611, United States.
Alfonso PepeDepartment of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL 32610, United States.
Diego PedroDepartment of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL 32610, United States.
Sadeem QdaisatLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, University of Florida Brain Tumor Immunotherapy Program, Gainesville, FL 32611, United States; University of Florida Genetics Institute, Gainesville, FL 32610, United States.
Nhi Tran Yen NguyenDepartment of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL 32610, United States.
Julia M LavradorDepartment of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL 32610, United States.
Griffin R GoldeDepartment of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL 32610, United States.
Ryan A SmolchekDepartment of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL 32610, United States.
John LigonDepartment of Pediatrics, Division of Pediatric Hematology Oncology, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32610, United States.
Linchun JinLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, University of Florida Brain Tumor Immunotherapy Program, Gainesville, FL 32611, United States.
Haipeng TaoLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, University of Florida Brain Tumor Immunotherapy Program, Gainesville, FL 32611, United States.
Alex WebberHerbert Wertheim College of Engineering, University of Florida, Gainesville, FL 32610, United States.
Simon PhillpotDepartment of Materials Science and Engineering, University of Florida, Gainesville, FL 32610, United States.
Duane A MitchellLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, University of Florida Brain Tumor Immunotherapy Program, Gainesville, FL 32611, United States.
Elias J SayourLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, University of Florida Brain Tumor Immunotherapy Program, Gainesville, FL 32611, United States.
Jianping HuangLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, University of Florida Brain Tumor Immunotherapy Program, Gainesville, FL 32611, United States. Electronic address: jianping.huang@neurosurgery.ufl.edu.
Paul CastilloDepartment of Pediatrics, Division of Pediatric Hematology Oncology, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32610, United States. Electronic address: castillopa@ufl.edu.
W Gregory SawyerDepartment of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL 32610, United States. Electronic address: wgsawyer@ufl.edu.
University of Florida · USAllen Institute for Brain Science · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable success as an immunotherapy for hematological malignancies, and its potential for treating solid tumors is an active area of research. However, limited trafficking and mobility of T cells within the tumor microenvironment (TME) present challenges for CAR T cell therapy in solid tumors. To gain a better understanding of CAR T cell function in solid tumors, we subjected CD70-specific CAR T cells to a challenge by evaluating their immune trafficking and infiltration through a confined 3D microchannel network in a bio-conjugated liquid-like solid (LLS) medium. Our results demonstrated successful CAR T cell migration and anti-tumor activity against CD70-expressing glioblastoma and osteosarcoma tumors. Through comprehensive analysis of cytokines and chemokines, combined with in situ imaging, we elucidated that immune recruitment occurred via chemotaxis, and the effector-to-target ratio plays an important role in overall antitumor function. Furthermore, through single-cell collection and transcriptomic profiling, we identified differential gene expression among the immune subpopulations. Our findings provide valuable insights into the complex dynamics of CAR T cell function in solid tumors, informing future research and development in this promising cancer treatment approach. STATEMENT OF SIGNIFICANCE: The use of specialized immune cells named CAR T cells to combat cancers has demonstrated remarkable success against blood cancers. However, this success is not replicated in solid tumors, such as brain or bone cancers, mainly due to the physical barriers of these solid tumors. Currently, preclinical technologies do not allow for reliable evaluation of tumor-immune cell interactions. To better study these specialized CAR T cells, we have developed an innovative in vitro three-dimensional model that promises to dissect the interactions between tumors and CAR T cells at the single-cell level. Our findings provide valuable insights into the complex dynamics of CAR T cell function in solid tumors, informing future research and development in this promising cancer treatment approach.

Indexed as

Bone NeoplasmsNeoplasmsReceptors, Chimeric AntigenAntigens, NeoplasmCell CommunicationHumansReceptors, Antigen, T-CellT-LymphocytesTumor MicroenvironmentAntigens, NeoplasmReceptors, Antigen, T-CellReceptors, Chimeric AntigenCancerCAR T traffickingChimeric antigen receptor (CAR) T cellCytotoxicityLiquid-like solid

Identifiers

PMID37788737
OpenAlexW4387232023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.